null

null

null

null

null

null

null

null

null

null

null

null

null

null

null

null

null

null

2.18x Total Debt / Equity (High leverage)

~$30M annual interest expense increase per 100bps on ~$3B variable-rate debt; 20bps shift impacts EBITDA by ~$6M, material given thin net margins

Low intensity; China and India supply >60% of global API inputs, creating concentration risk.

Domestic surgical supply distributors (Medline, Owens & Minor) and single-source medical device OEMs; geopolitical risk via China-manufactured surgical instruments and PPE

null

Predominantly US-only operations; no meaningful international revenue exposure; sovereign currency devaluation risk is effectively zero

Low intensity; commodities: Active Pharmaceutical Ingredients, Rare Earth Elements, Natural Gas (energy), Plastics/Resins, Ethanol, Packaging Materials; geopolitical: China and India supply >60% of global API inputs, creating concentration risk.

No single vendor exceeds 30% of input costs; GPO memberships (Premier, Vizient) diversify supply, but key implant OEMs (Stryker, Zimmer) create moderate non-substitutable procedure risk

Cloud disruption risk is low-moderate; clinical operations rely on EHR systems (Epic, Greenway) not public cloud; 30-day termination would disrupt billing and scheduling, not surgical delivery

Ambulatory surgical center (ASC) operator; fee-for-service healthcare services with partnership model alongside physician co-owners

EHR and practice management API coupling (Epic, Greenway Health) creates moderate lock-in; switching costs ~$500K-$2M per facility; replacement timeline 12-18 months

Low Howey risk; revenue model is direct fee-for-service surgical reimbursement from payors; no investment contract characteristics present

Very High

HIPAA-primary compliance environment; CCPA exposure moderate for California facilities; GDPR not applicable given US-only operations; PHI breach risk is primary regulatory exposure

Moderate; FTC scrutiny on hospital/ASC acquisitions rising; physician co-ownership and payor contracting concentration in regional markets creates antitrust review risk

Very High burden; regimes: FDA, CMS, HHS, HIPAA, EMA, OIG; Drug pricing legislation and approval delays directly compress revenue visibility.

~85% quasi-recurring (contracted payor reimbursement rates, multi-year payor agreements) but transactional per procedure; true subscription revenue near zero

Per-procedure fee collection from commercial insurers, Medicare, Medicaid; physician partnership revenue sharing; facility fee monetization primary vector

Payor-contracted rate architecture; limited direct pricing power; rate negotiations with commercial insurers every 2-3 years; Medicare/Medicaid rates set externally, ~40% of revenue

Moderate (3/5); commercial payor rates can be negotiated above inflation; government payor rates non-negotiable; ASC cost advantage over hospitals provides negotiating leverage

Gross margin ~20-25%; EBITDA margin ~10-13%; structurally constrained by physician distribution, supplies, and labor costs

Low free-rider risk; surgical procedures are non-substitutable, payor-gated services; patient volume tied to physician referral networks within owned facilities

Revenue growth is near headcount-linear; each new facility requires full clinical/administrative staffing; corporate overhead scales sublinearly but clinical labor dominates at ~35% of revenue

Greenfield ASC or acquisition requires $5-15M capex plus staffing ramp; marginal cost of growth high per facility but fixed costs spread over volume creates operating leverage at scale

Not a franchise model; physician partnership JV structure creates compliance drift risk in billing practices, credentialing, and quality metrics across 180+ facilities

At 10x scale, payor rate compression and physician recruitment scarcity would pressure unit economics; current ~$1,200-1,500 net revenue per case could compress 5-8%

Minimal network effects; scale benefits are procurement (GPO leverage) and payor contracting, not true network effects; physician referral density creates local quasi-network in markets

AI displacement risk low for surgical procedures; moderate for billing/coding (15-20% cost reduction potential); robotic surgery augments rather than displaces physician labor

Tier 2 (moderate resilience); elective surgical volumes decline 10-15% in recessions; non-elective and pain procedures more stable; ASC lower cost drives volume shift from hospitals

Commercial insurance payors (40-45% of revenue); no single payor likely exceeds 15-20% of revenue; UnitedHealth, BlueCross affiliates are likely top payors

Medicare/Medicaid (40%+ of revenue); government payor concentration creates reimbursement rate risk; CMS policy changes represent systemic revenue exposure

["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "19-0000 Life, Physical, and Social Science Occupations", "21-0000 Community and Social Service Occupations", "23-0000 Legal Occupations", "29-0000 Healthcare Practitioners and Technical Occupations", "31-0000 Healthcare Support Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "51-0000 Production Occupations"]

0.32 (HIL — ~32% of characteristic roles agent-automatable)

2.4% CapEx / Revenue (Low-CapEx Asset-Light)

0001638833

SGRY